We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hemogenyx Pharmaceuticals Plc | LSE:HEMO | London | Ordinary Share | GB00BYX3WZ24 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.015 | -0.96% | 1.55 | 1.538 | 1.60 | 1.55 | 1.55 | 1.55 | 4,707,352 | 14:44:44 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.98M | -0.0035 | -4.43 | 17.7M |
Date | Subject | Author | Discuss |
---|---|---|---|
08/3/2024 15:33 | The recent placement at 2p will allow the Company to progress HEMO-CAR-T to phase 1 clinical trials commencing shortly. Could even be news on this as early as next week? | apotheki | |
08/3/2024 13:27 | A couple of RNSs thrown in at the right time just to help the pump.The company, the mms and those cashing in on the raise all fleeced the innocent lambs BUT lets hope the science is strong enough to heal those wounds | saint in exile | |
08/3/2024 13:09 | So this was pumped to 6p so glad could get the placing away at 2p lots of forward sellingScna | beatme1 | |
08/3/2024 11:04 | Yes, scumbags like Apokethi / the chairman elect should consider that spamming threads with tips is not conducive to wealth creation for those caught on dogs like this. | premium beeks | |
08/3/2024 09:45 | This gets worse for those who were badly advised. Best not to give advice when you are not qualified. | countbasie1 | |
08/3/2024 07:40 | There are a lot of TROLLs around....so best to [as I do] just FILTER them all | apotheki | |
07/3/2024 21:22 | SteveA short closing would be a buy not a sell. | countbasie1 | |
07/3/2024 19:34 | Just saw that 12.1, hmmm, misprint and rollover could be I guess, that's a hell of a lot of stock for a rollover though. Dunno | jibba jabber | |
07/3/2024 17:14 | JJ Looks like a roll over. Sold then bought back cost taken at source It has been suggested elsewhere that the 12M + could be a Short closing then buying back. Either or is not bad news. | steveberyl | |
07/3/2024 16:37 | That 12.5ml looks interesting | jibba jabber | |
07/3/2024 10:51 | No i'm not Apotheki, the charts tell the story for me, time will tell as you say. | jibba jabber | |
07/3/2024 10:47 | I mentioned no names SNOWFLAKE, "But if the cap fits, wear it" Simple as. | steveberyl | |
07/3/2024 10:25 | Anyways unlike other posters I know that you are NOT outright de-ramping J J so good luck with it. With the end of the tax year in sight and markets historically weak at this time....whilst I seriously doubt it....you never know. | apotheki | |
07/3/2024 10:21 | i bet the charts at the end of premium beeks sick bed reads DNR...lol | dreamtwister | |
07/3/2024 10:21 | Sub 2p [sub the placing price] is a great buy but how much sub is up to the market and not any poster who wants to [de-ramp] so as to get back in at 1.35p or even lower. If it goes that low I will add a few more million to my current holding of [now] a few million! | apotheki | |
07/3/2024 10:14 | Historically it does seem to have good support off of 1.5p, i think 1.3-1.4 intraday is achievable free stock charts from uk.advfn.com | jibba jabber | |
07/3/2024 10:11 | Historically it does seem to have good support off of 1.5p, i think 1.3-1.4 intraday is achievable free stock charts from uk.advfn.com | jibba jabber | |
07/3/2024 09:46 | just to confirm The US Senate approved a bill on Wednesday (US time) to prohibit contracting with Chinese biotech providers. A bill moving through Congress is meant to effectively ban certain Chinese life sciences companies from doing business in the U.S., thereby preserving the competitive advantage of American drug manufacturers. But actually going through with it risks seriously hobbling the companies it’s purported to help. Many in Congress are worried the Chinese government and military are using the rising dominance of national companies to gather Americans’ genetic information, which could be used for reasons that range from creating bioweapons to giving China a leg up in drug development. so contracting with china biopharmaceuticals becomes functionally illegal then this will implement a restructure to the supply chain with the possibility of drug shortages.🐭 | dreamtwister | |
07/3/2024 09:13 | Yes, I expect so. I had some that I bought in Jan but held through the Feb rise, sold at a loss a week later. Annoying lack of discipline on my part but you learn and move on. What I can't abide are those (apotheki and his other / previous avatars) spamming threads with positive noises and then disappearing, only to appear with another pick a short time later. It's just straight book talking and abhorrent behaviour. At least go back and admit it wasn't a good buy. And here he is, still spouting the same rns's and trying to push the price, whilst he must know it's going nowhere for some time. A foreskin of the worst type unfortunately. Best filtered (as I have now). | premium beeks | |
07/3/2024 08:47 | I was looking at a 1.5 entry but something tells me 1.3 will be achievable. | jibba jabber | |
07/3/2024 08:32 | Apotheki advised Abbeygale to this buy under 2p.I hope they ignored that terrible advice. | countbasie1 | |
06/3/2024 12:05 | I sold after the recent positive update as Vlad has shown he can't be trusted to follow up. From the outside I only see this going to below 1.5 before people start to get speculative. They really do need to somehow shoehorn Vlad to just look after the science. | trying2trade | |
05/3/2024 18:03 | the recent placings will be added to the shares in issue march 6th. but also it is the day of the u k budget so investors can expect a blue day as Mr hunt eradicates the stamp duty sanctioned on the investment markets, also on this day The USA congress re-convenes ! | dreamtwister |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions